Holen Sie sich die Stockscreener-App
7.12
1.86%
0.13
Schlusskurs vom Vortag:
$6.99
Offen:
$6.98
24-Stunden-Volumen:
147.03K
Relative Volume:
0.17
Marktkapitalisierung:
$418.23M
Einnahmen:
-
Nettoeinkommen (Verlust:
-
KGV:
-7.857
EPS:
-0.9062
Netto-Cashflow:
-
1W Leistung:
-3.91%
1M Leistung:
-26.67%
6M Leistung:
+300.00%
1J Leistung:
+217.86%
1-Tages-Spanne:
$6.92
$7.55
1-Wochen-Bereich:
$6.56
$7.80
52-Wochen-Spanne:
$0.8786
$12.09
Adlai Nortye Ltd Adr Stock (ANL) Company Profile
Firmenname
Adlai Nortye Ltd Adr
Sektor
Branche
Telefon
-
Adresse
-
Compare ANL vs VRTX, REGN, ALNY, ARGX, INSM
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ANL
Adlai Nortye Ltd Adr
|
7.12 | 418.23M | 0 | 0 | 0 | -0.9062 |
VRTX
Vertex Pharmaceuticals Inc
|
454.97 | 115.58B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
749.47 | 79.23B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
328.70 | 43.59B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
697.05 | 43.26B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
148.31 | 31.97B | 606.42M | -1.28B | -997.58M | -6.403 |
Adlai Nortye Ltd Adr Stock (ANL) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-20 | Eingeleitet | Leerink Partners | Outperform |
| 2026-02-13 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2025-06-02 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2024-09-04 | Eingeleitet | H.C. Wainwright | Buy |
| 2023-10-24 | Eingeleitet | Cantor Fitzgerald | Overweight |
Adlai Nortye Ltd Adr Aktie (ANL) Neueste Nachrichten
Adlai Nortye Ltd. sponsored ADR (ANL) upgraded to buy: Here's why - MSN
Adlai Nortye Ltd. Sponsored ADR (ANL) Raised to Buy: The Reason Behind This Change - Bitget
Adlai Nortye Ltd. Sponsored ADR (ANL) Upgraded to Buy: Here's Why - Yahoo Finance
ETFs Investing in Adlai Nortye Ltd. Sponsored ADR Stocks - TradingView
Adlai Nortye (NASDAQ: ANL) files $600M shelf; 21.5M ADSs resale - Stock Titan
Is Adlai Nortye Ltd. Sponsored ADR (ANL) Outperforming Other Medical Stocks This Year? - Yahoo Finance
Analysts Offer Insights on Healthcare Companies: PepGen Inc. (PEPG) and Compass Therapeutics (CMPX) - The Globe and Mail
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: Fractyl Health, Inc. (GUTS), Ionis Pharmaceuticals (IONS) and Axsome Therapeutics (AXSM) - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: Iovance Biotherapeutics (IOVA) and Palvella Therapeutics (PVLA) - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: PDS Biotechnology (PDSB), Integer Holdings (ITGR) and Tonix Pharma (TNXP) - The Globe and Mail
Has Adlai Nortye Ltd. Sponsored ADR (ANL) Outpaced Other Medical Stocks This Year? - Yahoo Finance
Adlai Nortye upgraded to Buy at H.C. Wainwright as AN9025 enters clinic - TipRanks
H.C. Wainwright upgrades Adlai Nortye stock rating to Buy with $16 target - Investing.com South Africa
Adlai Nortye Doses First Patient in Global Phase 1 Trial of Pan-RAS Inhibitor AN9025 - TipRanks
Adlai Nortye Announces First Patient Enrolled in Global Phase 1 Trial of Pan-RAS (ON) Inhibitor AN9025 for Solid Tumors Harboring RAS Mutations - GlobeNewswire Inc.
Short Interest in Adlai Nortye Ltd. Sponsored ADR (NASDAQ:ANL) Rises By 458.7% - MarketBeat
Adlai Nortye Secures $140 Million PIPE Financing to Support Oncology Pipeline - The Globe and Mail
Adlai Nortye raises $140 million in private placement By Investing.com - Investing.com South Africa
Adlai Nortye prices 64.6M shares at $2.17 in private placement - TipRanks
Adlai Nortye raises $140 million in private placement - Investing.com
Adlai Nortye Ltd. Sponsored ADR (NASDAQ:ANL) Sees Large Decrease in Short Interest - Defense World
AIFU Inc. – Sponsored ADR (NASDAQ:AIFU) Short Interest Update - Defense World
United States shares mixed at close of trade; Dow Jones Industrial Average up 0.11% By Investing.com - Investing.com India
United States shares mixed at close of trade; Dow Jones Industrial Average up 0.11% - Investing.com India
U.S. stocks mixed at close of trade; Dow Jones Industrial Average up 0.11% - Investing.com
Lucid Capital Markets initiates coverage on Adlai Nortye stock with Buy rating - Investing.com India
Lucid Capital Markets initiates coverage on Adlai Nortye stock with Buy rating By Investing.com - Investing.com South Africa
Adlai Nortye Ltd. Sponsored ADR (NASDAQ:ANL) Short Interest Update - MarketBeat
Analysts’ Top Healthcare Picks: Kura Oncology (KURA), UnitedHealth (UNH) - The Globe and Mail
Analysts Are Bullish on Top Healthcare Stocks: Aprea Therapeutics (APRE), Arcellx Inc (ACLX) - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: Argenx Se (ARGX), Travere Therapeutics (TVTX) and Beyond Air (XAIR) - The Globe and Mail
Adlai Nortye Ltd. Sponsored ADR (NASDAQ:ANL) Sees Significant Increase in Short Interest - Defense World
Short Interest in Global X Social Media ETF (NASDAQ:SOCL) Increases By 7,184.3% - Defense World
TerraVest Industries (TSE:TVK) Price Target Raised to C$209.00 at Canaccord Genuity Group - Defense World
Paycom Software (NYSE:PAYC) Price Target Cut to $185.00 by Analysts at Barclays - Defense World
Teledyne Technologies (NYSE:TDY) Given New $579.00 Price Target at Barclays - Defense World
Adlai Nortye Ltd. Sponsored ADR (NASDAQ:ANL) Short Interest Up 6,821.4% in December - MarketBeat
Adlai Nortye narrows first-half 2025 loss as oncology pipeline advances - MSN
Why Baidu Shares Are Trading Higher By Over 12%; Here Are 20 Stocks Moving Premarket - Sahm
Adlai Nortye Ltd. Shareholders Approve Redomiciliation to Singapore - MSN
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Xoma (XOMA) and Adlai Nortye Ltd. Sponsored ADR (ANL) - The Globe and Mail
Why Fonar Shares Are Trading Higher By Over 24%; Here Are 20 Stocks Moving Premarket - Sahm
Adlai Nortye Ltd ADR (ANL-Q) Stock Price and News - The Globe and Mail
Adlai Nortye licenses cancer drug to ASK Pharm in $230 million deal By Investing.com - Investing.com South Africa
Adlai Nortye shares soar on $230 million licensing deal with ASK Pharm By Investing.com - Investing.com South Africa
Adlai Nortye shares soar on $230 million licensing deal with ASK Pharm - Investing.com India
Adlai Nortye Narrows First-Half 2025 Loss as Oncology Pipeline Advances - TipRanks
Adlai Nortye Licenses Pan-RAS Inhibitor AN9025 to ASK Pharm for Greater China - TipRanks
Adlai Nortye licenses cancer drug to ASK Pharm in $230 million deal - Investing.com
Adlai Nortye Enters Exclusive License Agreement with ASK Pharm for Pan-RAS (ON) Inhibitor AN9025 in Greater China - Sahm
Finanzdaten der Adlai Nortye Ltd Adr-Aktie (ANL)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.82%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):